Leveraging the Unique Power of Chemoproteomics for Hit Identification & Screening to Transform Discovery of Therapeutic Candidates
- Explore the Frontier Platform which combines chemoproteomics, covalent fragment-based discovery, and AI to access more than 90% of the proteome
- Discover how a custom-built covalent fragment library that leverages the concept of enantiomer pairs was used to reveal immediate SAR through enantiomer-specific hits, enabled by chemoproteomic screening in live cells capturing proteome-wide engagement signatures
- Presenting novel quality-control metrics for large-scale chemoproteomic screening of covalent enantiomer libraries, complementing compound purity checks and improving triage of true hits for downstream assays